Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2024 Jul 9;68(7):e0023624.
doi: 10.1128/aac.00236-24. Epub 2024 May 23.

Patient outcomes by baseline pathogen resistance phenotype and genotype in CERTAIN-1, a Phase 3 study of cefepime-taniborbactam versus meropenem in adults with complicated urinary tract infection

Greg Moeck  1 , Leanne B Gasink  2 , Rodrigo E Mendes  3 , Leah N Woosley  3 , MaryBeth Dorr  1 , Hongzi Chen  1 , Florian M Wagenlehner  4 , Tim Henkel  1 , Paul C McGovern  1
Affiliations
Clinical Trial

Patient outcomes by baseline pathogen resistance phenotype and genotype in CERTAIN-1, a Phase 3 study of cefepime-taniborbactam versus meropenem in adults with complicated urinary tract infection

Greg Moeck et al. Antimicrob Agents Chemother. .

Abstract

CERTAIN-1 was a Phase 3, double-blind, randomized, parallel group study of the efficacy and safety of cefepime-taniborbactam versus meropenem in the treatment of adults with complicated urinary tract infection (cUTI), including acute pyelonephritis. We determined susceptibility of Enterobacterales and Pseudomonas aeruginosa baseline pathogens to cefepime-taniborbactam and comparators and characterized β-lactam resistance mechanisms. Microbiologic response and clinical response were assessed in patient subsets defined by baseline pathogens that were of cefepime-, multidrug-, or carbapenem-resistant phenotype or that carried β-lactamase genes. Among Enterobacterales baseline pathogens, 26.8%, 4.1%, and 3.0% carried genes for extended-spectrum β-lactamases (ESBLs), AmpC, and carbapenemases, respectively. Within each treatment group, while composite success rates at Test of Cure in resistant subsets by pathogen species were similar to those by pathogen overall, composite success rates in meropenem patients were numerically lower for cefepime-resistant Escherichia coli (9/19; 47.4%) and ESBL E. coli (13/25; 52.0%) compared with E. coli overall (62/100; 62.0%). Cefepime-taniborbactam achieved composite success in 7/8 (87.5%) patients with carbapenem-resistant Enterobacterales and 8/9 (88.9%) patients with Enterobacterales with a carbapenemase gene (5 OXA-48-group; 2 KPC-3; 2 NDM-1). Cefepime-taniborbactam also achieved composite success in 8/16 (50.0%) patients and clinical success in 13/16 (81.3%) patients with P. aeruginosa; corresponding rates were 4/7 (57.1%) and 6/7 (85.7%) for meropenem. Cefepime-taniborbactam demonstrated efficacy in adult cUTI patients with cefepime-, multidrug-, and carbapenem-resistant pathogens including pathogens with ESBL, AmpC, and carbapenemase genes.

Clinical trials: This study is registered with ClinicalTrials.gov as NCT03840148.

Keywords: carbapenemase; cefepime-taniborbactam; complicated urinary tract infection; meropenem; outcome; β-lactamase inhibitor.

PubMed Disclaimer

References

    1. World Health Organization . 2017. Prioritization of pathogens to guide discovery, research and development of new antibiotics for drug-resistant bacterial infections,including tuberculosis. World Health Organization (WHO), Geneva.
    1. CDC . 2019. Antibiotic resistance threats in the United States, 2019. Vol. 139. Atlanta, GA: Centers for Disease Control and Prevention (CDC). doi:10.15620/cdc:82532 - DOI
    1. Castanheira M, Doyle T, Kantro V, Mendes RE, Sader HS. 2022. 664. Increase in the occurrence of carbapenem-resistant Enterobacterales (CRE) in United States (US) hospitals from 2019 to 2021 and activity of novel β-lactam/β-lactamase Inhibitor (BL/BLI) combinations against these isolates. Open Forum Infect Dis 9. doi:10.1093/ofid/ofac492.716 - DOI
    1. Tenover FC, Nicolau DP, Gill CM. 2022. Carbapenemase-producing Pseudomonas aeruginosa –an emerging challenge. Emerg Microbes Infect 11:811–814. doi:10.1080/22221751.2022.2048972 - DOI - PMC - PubMed
    1. Estabrook M, Muyldermans A, Sahm D, Pierard D, Stone G, Utt E. 2023. Epidemiology of resistance determinants identified in meropenem-nonsusceptible Enterobacterales collected as part of a global surveillance study, 2018 to 2019. Antimicrob Agents Chemother 67:e0140622. doi:10.1128/aac.01406-22 - DOI - PMC - PubMed

Publication types

MeSH terms

Associated data